CClinicalTrials.gg
RecruitingNCT05947253Updated Jul 17, 2023

Comparative Effects of BBT and Active Cycle of Breathing Technique on Dyspnea and Quality of Life in COPD

An interventional study of Buyteko breathing technique and active cycle of breathing technique in COPD, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

Comparative effects of Butyeko breathing technique and Active Cycle of Breathing technique on dyspnea and quality of life in patients with chronic obstructive pulmonary disease

Read the detailed description

A comparative study to determine the effects of butyeko breathing techniques and Active Cycle of Breathing technique on dyspnea and quality of life in patients with chronic obstructive pulmonary disease. As few researches on Butyeko breathing techniques are still present on COPD most of them are on asthma. The goal of the Butyeko Method is to improve breathing patterns, as indicated by achieving a higher breath hold time (control pause). Every five seconds improvement to the control pause, results in an alleviation of breathing difficulty and improved control of COPD The Butyeko method is a purported method of "retraining" the body's breathing pattern to correct for the presumed chronic hyperventilation and hypocapnea, and thereby treat or cure the body of these medical problems. Patients with chronic obstructive pulmonary disease (COPD) often suffer from expectoration. To address this problem, active cycle of breathing techniques (ACBT) can be applied in patients of COPD. In our study daily Butyeko breathing exercise and active cycle of breathing technique session of 30 to 35 minutes will be given to patients and effects of both techniques will be compared.

A randomized clinical trial will be conducted using convenient sampling or randomized sampling technique in population of chronic obstructive pulmonary disease (COPD).Total sample size will be of 40 and two Groups will be made Group A 20 participants received Buyteko breathing technique and Groups B 20 participants received Active cycle of breathing technique. Data will be collected by using Borg's dyspnea scale, St.George Respiratory questionnaire and by pulmonary function testing. Data will be collected from pulmonary ward Jinnah hospital Lahore whole study will take total duration of 10 months and data will be analyzed using latest version of SPSS-25 software.

02

Conditions studied

  • COPD

Browse trials for

Keywords

  • Buteyko breathing technique
03

In context

Dyspnea

656 studies on the registry are indexed under Dyspnea; 153 are open to participants now.

This study's planned enrollment of 40 is below the median of 48 across 430 interventional studies indexed under Dyspnea.

Browse Dyspnea studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,133 studies on the registry; 633 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of COPD confirmed by smoking history.
  • PFT showing irreversible airflow limitation.
  • Patients hemodynamically stable.
  • Males and females.
  • Patients capable of completing IPAQ questionnaire

Exclusion criteria

Exclusion Criteria:

  • Evidence of unstable cardiac disease, Pulmonale decompensation
  • Disabling diseases which prevented participation in the exercise program, such as orthopedic inabilities or peripheral vascular disease.
  • Systemic illness.
  • Resting O2 saturation \<90% with room air breathing and Patient with viral infection
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    BUTYEKO BREATHING TECHNIQUE

    First Group A 20 participants received Buyteko breathing technique while will be given 5 days per week

    Other: Buyteko breathing technique

  • Experimental
    active cycle of breathing technique

    Group B 20 participants received active cycle of breathing technique and session of 35min will be given 5 days per week

    Other: active cycle of breathing technique

Interventions

  • OtherBuyteko breathing technique

    group A 20 participants received Buyteko breathing technique 2 session for 3 weeks

  • Otheractive cycle of breathing technique

    Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks

06

What researchers measure

Primary outcomes

  1. Borg's dyspnea scale.

    For the measurement of dyspnea The Modified Borg Dyspnea Scale (MBS) is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered during six-minute walk testing (6MWT

    Time frame: 4 weeks

  2. Spirometry

    Spirometry is the most common of the pulmonary function tests. It measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled. Spirometry is helpful in assessing breathing patterns that identify conditions such as asthma, Chronic obstructive pulmonary disease

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Pulmonary ward Jinnah hospital Lahore.
    Lahore, Punjab 54000, Pakistan
    Recruiting
08

References and documents

Publications

  • Vogelmeier CF, Roman-Rodriguez M, Singh D, Han MK, Rodriguez-Roisin R, Ferguson GT. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020 May;166:105938. doi: 10.1016/j.rmed.2020.105938. Epub 2020 Mar 21. PubMed 32250871 ↗
  • May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015 Jan-Feb;36(1):4-10. doi: 10.2500/aap.2015.36.3812. PubMed 25562549 ↗
  • Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006 Sep;3(7):619-23. doi: 10.1513/pats.200603-093SS. PubMed 16963544 ↗
  • Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942128. doi: 10.1177/1753466620942128. PubMed 32664818 ↗
  • Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:871-88. doi: 10.2147/COPD.S49621. eCollection 2014. PubMed 25210449 ↗
  • Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006 Feb;27(2):397-412. doi: 10.1183/09031936.06.00025805. No abstract available. PubMed 16452599 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05947253
Lead sponsor
Riphah International University
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
May 15, 2023
Primary completion
Oct 10, 2023 (estimated)
Completion
Dec 15, 2023 (estimated)
Last update
Jul 17, 2023

Study contacts

Iqbal Tariq, PHD
Contact
iqbal.tariq@riphah.edu.pk
O3338236752
Sidra Faisal, MS.CPPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion